This was the stock's second consecutive day of losses.

Biotech M&A is heating up, making small-cap firms with breakthrough assets top acquisition targets and potential big winners ...

Shares of Ocugen Inc. OCGN rallied 5.49% to $1.04 Tuesday, on what proved to be an all-around great trading session for the ...

Shares of Ocugen are trading lower Monday afternoon. The company earlier announced a definitive agreement to merge its subsidiary OrthoCellix with Carisma Therapeutics.

Ocugen, a company in the healthcare sector, has experienced a notable decline in its stock price over the past week, dropping by 8.62%. Despite this downturn, analysts like Robert ...

The biotech plans to use one-year follow-up data from the Phase II/III trial to support a biologics license application for OCU410ST in 2027.

Ocugen has a valuable IP portfolio, which should give it funding options. OCGN’s cash runway remains the main risk. Check out ...

The US FDA has approved Ocugen’s IND amendment to commence a Phase II/III pivotal confirmatory study of OCU410ST.

Ocugen's gene therapy for Stargardt disease is now advancing to a pivotal trial. The company's treatment could help patients ...

OCU410ST employs an adeno-associated virus platform for retinal delivery of the RORA gene, targeting Stargardt disease ...

The OCU410ST Phase 2/3 pivotal confirmatory trial represents a major advancement as Ocugen's second late-stage clinical program. Ocugen plans to submit a BLA for OCU410ST in 2027 in alignment with its ...

NextCure gains global rights to SIM0505 excluding greater China, where Simcere Zaiming will retain rights; Phase 1 clinical ...